NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 9061S 
Neuropharm Group PLC 
28 May 2009 
 

+------------------------------------------+------------------------------------+ 
| For immediate release                    |                        28 May 2009 | 
+------------------------------------------+------------------------------------+ 
 
 
 
 
 
 
Neuropharm Group plc 
("Neuropharm" or "the Company") 
 
 
Shareholder Update 
 
 
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on 
 neurodevelopmental disorders, today announces an interim update to its 
shareholders on significant progress during the past three months. 
 
 
On 18 February 2009 the Company announced the top-line results for the SOFIA 
study in Autistic Disorder of NPL-2008, a novel formulation of fluoxetine, which 
showed that this study had not met its primary endpoint of demonstrating a 
statistically significant difference between NPL-2008 and placebo treatment. 
 
 
The Company has largely completed the analysis of the results from this study 
and is now in discussion with clinicians and experts in the field, who continue 
to express strong support for the product. In addition, following considerable 
interest in NPL-2008 from a number of parties, discussions have progressed well 
with a third party pharmaceutical company for a potential collaboration which 
would encompass the further development and commercialisation of NPL-2008. 
Neuropharm is therefore  developing study designs for a second Phase III study, 
in conjunction with the partner. 
 
 
Neuropharm's intention would be to conduct a further Phase III study for 
NPL-2008 with a modified trial design, incorporating the important findings and 
insights from SOFIA, which will be funded through the collaboration.  It is 
expected that a deal will be signed by the autumn of this year. 
 
 
 
 
 
 
For further information please contact: 
 
 
+-----------------------------------------------+--------------------+ 
| Neuropharm                                    |  + 44 (0) 1372 371 | 
|                                               |                171 | 
+-----------------------------------------------+--------------------+ 
| Robert Mansfield, Chief Executive Officer     |                    | 
| Graham Yeatman, Chief Financial Officer       |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Piper Jaffray Ltd.                            |   + 44 (0) 20 3142 | 
|                                               |               8700 | 
+-----------------------------------------------+--------------------+ 
| Neil Mackison, Rupert Winckler                |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Buchanan Communications                       |   + 44 (0) 20 7466 | 
|                                               |               5000 | 
+-----------------------------------------------+--------------------+ 
| Mark Court, Mary-Jane Johnson, Catherine      |                    | 
| Breen                                         |                    | 
+-----------------------------------------------+--------------------+ 
 
 
Notes to Editors: 
 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCPUUCWAUPBGAM 
 

Neuropharm (LSE:NPH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Neuropharm (LSE:NPH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024